MA47824A - Administration polyanionique d'acides nucléiques - Google Patents
Administration polyanionique d'acides nucléiquesInfo
- Publication number
- MA47824A MA47824A MA047824A MA47824A MA47824A MA 47824 A MA47824 A MA 47824A MA 047824 A MA047824 A MA 047824A MA 47824 A MA47824 A MA 47824A MA 47824 A MA47824 A MA 47824A
- Authority
- MA
- Morocco
- Prior art keywords
- polyanionic
- administration
- nucleic acids
- nucleic
- acids
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/02—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton
- C07C305/04—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton being acyclic and saturated
- C07C305/06—Hydrogenosulfates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468244P | 2017-03-07 | 2017-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47824A true MA47824A (fr) | 2020-01-15 |
Family
ID=61764150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047824A MA47824A (fr) | 2017-03-07 | 2018-03-07 | Administration polyanionique d'acides nucléiques |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10961184B2 (fr) |
| EP (1) | EP3592728A1 (fr) |
| MA (1) | MA47824A (fr) |
| WO (1) | WO2018165257A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853377B2 (en) * | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| JP7423522B2 (ja) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
| EP3793689A1 (fr) * | 2018-05-15 | 2021-03-24 | Translate Bio, Inc. | Administration sous-cutanée d'arn messager |
| CN112888451A (zh) | 2018-10-19 | 2021-06-01 | 川斯勒佰尔公司 | 信使rna的无泵包封 |
| US12280147B2 (en) | 2018-11-09 | 2025-04-22 | Translate Bio, Inc. | PEG lipidoid compounds |
| US12357705B2 (en) * | 2018-11-09 | 2025-07-15 | Arbutus Biopharma Corporation | Negatively charged peg-lipid conjugates |
| US20220016265A1 (en) | 2018-11-09 | 2022-01-20 | Translate Bio, Inc. | Messenger rna therapy for treatment of ocular diseases |
| JP2022516356A (ja) * | 2019-01-07 | 2022-02-25 | トランスレイト バイオ， インコーポレイテッド | 原発性線毛機能不全症の治療のための組成物および方法 |
| JP7586886B2 (ja) | 2019-07-08 | 2024-11-19 | トランスレイト バイオ， インコーポレイテッド | 改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス |
| US12514932B2 (en) | 2020-05-14 | 2026-01-06 | Translate Bio, Inc. | PEG lipidoid compounds |
| EP4229208A4 (fr) | 2020-10-14 | 2024-10-30 | George Mason Research Foundation, Inc. | Méthodes de fabrication de nanoparticules lipidiques et compositions dérivées de celles-ci |
| CN115300609A (zh) * | 2021-05-08 | 2022-11-08 | 西湖大学 | 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用 |
| WO2022241045A1 (fr) | 2021-05-12 | 2022-11-17 | The Broad Institute, Inc. | Arnm modifié, arn non codant modifié, et leurs utilisations |
| EP4395748A1 (fr) | 2021-09-03 | 2024-07-10 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| EP4469091A1 (fr) | 2022-01-28 | 2024-12-04 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024230934A1 (fr) | 2023-05-11 | 2024-11-14 | CureVac SE | Acide nucléique thérapeutique pour le traitement de maladies ophtalmiques |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| EP1766035B1 (fr) | 2004-06-07 | 2011-12-07 | Protiva Biotherapeutics Inc. | Arn interferant encapsule dans des lipides |
| WO2008016473A2 (fr) | 2006-07-28 | 2008-02-07 | Applera Corporation | ANALOGUES DE COIFFES DE NUCLÉOTIDE D'ARNm |
| WO2009058911A2 (fr) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Préparation et isolement d'un arnm coiffé en 5' |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| WO2010053572A2 (fr) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Lipidoïdes aminoalcool et leurs utilisations |
| JP4857373B2 (ja) * | 2009-09-09 | 2012-01-18 | 国立大学法人東京農工大学 | デンドリマー被覆磁気微粒子並びにその製造方法及び用途 |
| ME03091B (fr) | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines |
| EP3998064A1 (fr) | 2011-06-08 | 2022-05-18 | Translate Bio, Inc. | Lipides clivables |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| EP2535326A1 (fr) * | 2011-06-16 | 2012-12-19 | Koninklijke Philips Electronics N.V. | Nouveaux composés lipidomimétiques et leurs utilisations |
| MX363734B (es) | 2011-10-27 | 2019-03-29 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco. |
| KR20150127582A (ko) | 2013-03-14 | 2015-11-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | 4''-티오 개질된 뉴클레오티드를 갖는 리보핵산 및 관련 방법 |
| ES3032013T3 (en) * | 2013-03-15 | 2025-07-14 | Translate Bio Inc | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| DK3145984T3 (da) * | 2014-05-21 | 2022-04-11 | Icd Therapeutics Gmbh | Terapeutiske konjugater med sulfaterede dendrimerer til intracellulær målretning |
-
2018
- 2018-03-07 EP EP18713102.4A patent/EP3592728A1/fr not_active Withdrawn
- 2018-03-07 WO PCT/US2018/021292 patent/WO2018165257A1/fr not_active Ceased
- 2018-03-07 US US16/491,475 patent/US10961184B2/en active Active
- 2018-03-07 MA MA047824A patent/MA47824A/fr unknown
-
2021
- 2021-02-10 US US17/172,640 patent/US11427535B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10961184B2 (en) | 2021-03-30 |
| EP3592728A1 (fr) | 2020-01-15 |
| US11427535B2 (en) | 2022-08-30 |
| US20200017440A1 (en) | 2020-01-16 |
| US20210261502A1 (en) | 2021-08-26 |
| WO2018165257A1 (fr) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47824A (fr) | Administration polyanionique d'acides nucléiques | |
| IL283179A (en) | Fusosome compositions for cns delivery | |
| IL288461A (en) | Targeted nucleic acid conjugate compositions | |
| MA52709A (fr) | Administration d'adn | |
| EP3433382A4 (fr) | Spike-ins d'acides nucléiques synthétiques | |
| MA48050A (fr) | Lipides biodégradables pour l'administration d'acides nucléiques | |
| EP3414327A4 (fr) | Détection d'acides nucléiques | |
| EP3294212A4 (fr) | Administration de médicament à partir d'hydrogels | |
| MA47680A (fr) | Arn thérapeutique | |
| EP3463228A4 (fr) | Administration intraoculaire de médicaments | |
| EP3431075C0 (fr) | Forme galénique d'édaravone | |
| EP3409780A4 (fr) | Complexe d'acides nucléiques | |
| IL258366B (en) | Pharmaceutical compositions of il-2 | |
| EP3352795A4 (fr) | Compositions et méthodes de modification d'acides nucléiques cibles | |
| MA49393A (fr) | Poly(phosphoesters) destinés à l'administration d'acides nucléiques | |
| EP3603642A4 (fr) | Préparation pharmaceutique | |
| EP3525841A4 (fr) | Micro-dispositif d'administration | |
| EP3380637A4 (fr) | Détermination de méthylation d'acides nucléiques | |
| EP3643353A4 (fr) | Robot d'administration de médicament | |
| EP3498724A4 (fr) | Complexe d'acides nucléiques | |
| EP3366773A4 (fr) | Complexe d'acides nucléiques | |
| EP3394099A4 (fr) | Formulations d'anticorps anti-il-10 modifiés | |
| EP3442544A4 (fr) | Méthodes améliorées d'administration de gènes | |
| EP3454847A4 (fr) | Formulations de médicaments améliorées | |
| EP3377512A4 (fr) | Promédicaments d'acides nucléiques |